PD-L1 expression (median: 45%, range 1–100%) on tumor as evaluated with VENTANA PD-L1 (SP263) Assay (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Basel, Switzerland) was done in 30 (77%) patients. This evidence concerns the gene CD274 and neoplasm.